CompletedNCT02051413
Blood Markers and Response to Venlafaxine for Depression
About this title
Read the official source — NCT02051413Medication studyAges 18–65France
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- Le Kremlin-BicêtreSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateStarted: February 18, 2014
- Recruitment status
- Completed
- Enrollment listed in the registry
- 67
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
- Sponsor type
- Research institute
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- France
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT02051413
- Official title
Show the full official title
Beta-arrestins and Response to Venlafaxine in Major Depressive Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Le Kremlin-Bicêtre
Questions about this study
Who is behind this study?
The study sponsor is Institut National de la Santé Et de la Recherche Médicale, France, a research institute.
Did this study involve medication?
Yes. The study involved medication, including Venlafaxine extended release.
Who was this study for?
Listed age limits: 18 years to 65 years.
Want to explore more studies?
Explore studiesRelated studies
Intranasal Esketamine Added to Standard Care for Adults at Imminent Suicide Risk
A 24-Week, Flexible-Dose, Open-label Extension Study of Lurasidone for the Treatment of Bipolar I Depression